These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 31601406)

  • 1. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
    Elsaid S; Kloiber S; Le Foll B
    Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
    Crippa JA; Guimarães FS; Campos AC; Zuardi AW
    Front Immunol; 2018; 9():2009. PubMed ID: 30298064
    [No Abstract]   [Full Text] [Related]  

  • 4. Cannabidiol, neuroprotection and neuropsychiatric disorders.
    Campos AC; Fogaça MV; Sonego AB; Guimarães FS
    Pharmacol Res; 2016 Oct; 112():119-127. PubMed ID: 26845349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
    Bonaccorso S; Ricciardi A; Zangani C; Chiappini S; Schifano F
    Neurotoxicology; 2019 Sep; 74():282-298. PubMed ID: 31412258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological Aspects of Medical Use of Cannabidiol.
    Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
    CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
    Newton M; Newton DW
    J Am Psychiatr Nurses Assoc; 2020; 26(5):447-457. PubMed ID: 32508204
    [No Abstract]   [Full Text] [Related]  

  • 8. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
    Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Pina SD; Tambaro S; Memo M; Mastinu A
    Life Sci; 2019 May; 224():120-127. PubMed ID: 30910646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
    Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
    BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
    Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
    Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.
    Ożarowski M; Karpiński TM; Zielińska A; Souto EB; Wielgus K
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
    Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
    Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
    Zlebnik NE; Cheer JF
    Annu Rev Neurosci; 2016 Jul; 39():1-17. PubMed ID: 27023732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for cannabidiol in psychiatry?
    Khoury JM; Neves MCLD; Roque MAV; Queiroz DAB; Corrêa de Freitas AA; de Fátima Â; Moreira FA; Garcia FD
    World J Biol Psychiatry; 2019 Feb; 20(2):101-116. PubMed ID: 28112021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.
    Ortiz R; Rueda S; Di Ciano P
    Exp Clin Psychopharmacol; 2023 Oct; 31(5):978-988. PubMed ID: 37126037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A scoping review of the use of cannabidiol in psychiatric disorders.
    Kirkland AE; Fadus MC; Gruber SA; Gray KM; Wilens TE; Squeglia LM
    Psychiatry Res; 2022 Feb; 308():114347. PubMed ID: 34952255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
    Zuardi AW
    Braz J Psychiatry; 2008 Sep; 30(3):271-80. PubMed ID: 18833429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
    García-Gutiérrez MS; Navarrete F; Gasparyan A; Austrich-Olivares A; Sala F; Manzanares J
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol: Pharmacodynamics and pharmacokinetic in the context of neuropsychiatric disorders.
    Lirio PHC; Gaspari PDM; Campos AC
    Int Rev Neurobiol; 2024; 177():11-27. PubMed ID: 39029981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.